Samsara BioCapital

Samsara BioCapital is a Palo Alto-based venture firm that invests in life sciences companies, with a focus on biotech and pharma and therapeutics. The firm supports founders and management teams whose programs are grounded in rigorous biological insight and have the potential to translate into meaningful therapeutic outcomes. Its position in Palo Alto provides direct access to West Coast biotech ecosystems, leading research institutions, and the broader network of specialist life sciences investors. Specific portfolio company names and partner detail are not provided in the input, so this profile relies on the firm’s stated focus and structural characteristics.

Samsara writes checks of $5M to $25M and invests across Seed, Series A, Series B, and Series C stages. Headquartered in the United States, the firm’s multi-stage posture allows it to support companies from early formation through clinical advancement, often participating across multiple rounds. The stage breadth means the firm engages both with newly formed companies built around novel science and with companies that are already advancing programs into and through clinical development.

For founders and management teams, Samsara is most relevant when a biotech or pharma program is built on rigorous science and has a credible therapeutic hypothesis that can be tested through well-designed clinical work. The firm prefers teams that engage directly on biological mechanism, data, and clinical strategy. Founders should expect detailed scientific diligence, a partner with depth in life sciences syndicates, and engagement on team building, board governance, and the financing strategy required to move programs through long, capital-intensive development arcs.